Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, UK.
Ann Surg Oncol. 2022 Apr;29(4):2607-2613. doi: 10.1245/s10434-021-10994-z. Epub 2021 Nov 3.
The WHO classification of mucinous appendix neoplasms and pseudomyxoma peritonei (PMP) describes low- and high-grade histology and is of prognostic importance. The metastatic peritoneal disease grade can occasionally be different from the primary appendix tumor. This analysis aimed to report outcomes from a high-volume center in patients with pathological discordance.
This was a retrospective analysis of prospective data of patients treated by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for PMP at a single institution between January 2016 and December 2020. Reporting was by pathologists with a special interest in peritoneal malignancy. Discordant pathology was classified as a low-grade primary appendix tumor with high-grade peritoneal disease, or a high-grade primary appendix tumor with low-grade peritoneal disease. Outcomes analyzed were overall and recurrence-free survival, and Kaplan-Meier survival curves and the log-rank test were used to analyze the outcomes.
Between 2016 and 2020, 830 patients underwent CRS and HIPEC for PMP, of whom 37 (4.4%) had discordant pathology. The primary appendix tumors were low-grade in 23 patients and high-grade in 14 patients. The median Peritoneal Cancer Index (PCI) was significantly higher in patients with a low-grade primary tumor (31 vs. 16; p = 0.001), while complete cytoreduction (CC0/1) was achieved in 31/37 (83.8%) patients. The median follow-up was 19 months. Overall survival was worse in those with high-grade peritoneal disease (p = 0.029), whereas recurrence-free survival was similar in both groups (p = 0.075).
In PMP with pathological discordance, the peritoneal disease grade influences prognosis and survival.
世界卫生组织(WHO)对阑尾黏液性肿瘤和假性黏液瘤腹膜转移(PMP)的分类描述了低级别和高级别组织学,并具有预后意义。转移性腹膜疾病的分级偶尔与原发性阑尾肿瘤不同。本分析旨在报告高容量中心的病理不一致患者的结果。
这是对一家机构在 2016 年 1 月至 2020 年 12 月期间接受细胞减灭术(CRS)和腹腔热灌注化疗(HIPEC)治疗 PMP 的前瞻性数据的回顾性分析。报告由对腹膜恶性肿瘤有特殊兴趣的病理学家进行。病理不一致分为低级别原发性阑尾肿瘤伴高级别腹膜疾病,或高级别原发性阑尾肿瘤伴低级别腹膜疾病。分析的结果是总生存率和无复发生存率,使用 Kaplan-Meier 生存曲线和对数秩检验分析结果。
在 2016 年至 2020 年间,830 例患者接受了 CRS 和 HIPEC 治疗 PMP,其中 37 例(4.4%)存在病理不一致。23 例原发性阑尾肿瘤为低级别,14 例为高级别。低级别原发性肿瘤患者的腹膜癌指数(PCI)中位数明显较高(31 比 16;p=0.001),而 37 例(83.8%)患者达到完全肿瘤减灭术(CC0/1)。中位随访时间为 19 个月。高级别腹膜疾病患者的总生存率较差(p=0.029),而两组患者的无复发生存率相似(p=0.075)。
在具有病理不一致的 PMP 中,腹膜疾病分级影响预后和生存。